The chemical class denoted as DMXL2 Inhibitors refers to a collection of compounds that can interact with and influence the cellular and molecular processes associated with the function of the DMXL2 protein. While not directly interacting with DMXL2 itself, these chemicals exert their influence on various components of the signaling pathways and synaptic mechanisms that DMXL2 is understood to be a part of. This includes the modulation of vesicular trafficking, synaptic vesicle cycling, and neurotransmitter release, all of which are integral to the normal functioning of neuronal communication. The compounds range from those affecting ion channels and transporters, such as Tetrodotoxin and Bafilomycin A1, to those modulating cytoskeletal dynamics, like Latrunculin A and Y-27632. These chemicals can influence the activity of neurons at the synaptic level, thereby affecting the overall process of neurotransmission, within which DMXL2 plays a contributory role.
The actions of these inhibitors span various biological processes. For instance, Tetrodotoxin's inhibition of voltage-gated sodium channels can suppress neuronal excitability, leading to downstream effects on vesicle mobilization and release, processes in which DMXL2 may be implicated. Similarly, calcium channel blockers like Nifedipine can affect the influx of calcium ions, which is crucial for the release of neurotransmitters, potentially altering the activity of DMXL2-associated pathways. Moreover, compounds like Forskolin, which can raise intracellular cAMP levels, can also modulate neurotransmitter release and thereby influence synaptic mechanisms that include DMXL2 function. This class of inhibitors does not target DMXL2 directly; instead, their action is based on the alteration of the broader cellular environment and regulatory systems that support the functional role of DMXL2, thereby modulating its activity in an indirect manner. Each inhibitor functions within a unique mechanism of action, but together they represent a strategic approach to modulating the protein's activity by targeting the nuanced interplay of signaling pathways in the neuron.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A vacuolar H+ ATPase inhibitor that can disrupt neurotransmitter storage by affecting vesicular pH and indirectly influencing DMXL2. | ||||||
Clonidine | 4205-90-7 | sc-501519 | 100 mg | $240.00 | 1 | |
An adrenergic agonist that may alter neurotransmission and could affect the synaptic processes regulated by DMXL2. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A dynamin inhibitor that can impair vesicle scission, potentially affecting vesicle cycling and DMXL2 function. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Disrupts actin polymerization, which can alter cytoskeletal dynamics critical for vesicle trafficking, potentially impacting DMXL2. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
A calcium channel blocker that may influence vesicle release and indirectly modulate DMXL2 function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Activates adenylate cyclase, increasing cAMP and potentially influencing neurotransmitter release mechanisms involving DMXL2. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that affects actin cytoskeleton organization and could indirectly impact vesicle trafficking associated with DMXL2. | ||||||